Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes

In this discussion panel with Pharmacy Times, Meredith Pelster, MD, MSCI, associate director of GI cancer research at Sarah Cannon Research Institute and a medical oncologist at SCRI Oncology Partners, and Ben Zeskind, PhD, CEO and co-founder of Immuneering, discuss emerging data that could meaningfully change the treatment landscape for pancreatic cancer. The panel highlights the significance of a 64% overall survival rate at 12 months in the first-line metastatic setting, a notable departure from historically poor outcomes where fewer than half of patients survive beyond one year. Pelster emphasizes how this improvement could fundamentally alter conversations with patients at diagnosis, offering greater hope for durable benefit earlier in the disease course. Zeskind explains how alignment between progression-free survival and overall survival strengthens confidence in the clinical signal and supports advancement into larger randomized trials.